Latest Breaking News On - Efficacy comparison - Page 1 : comparemela.com

Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks Horizon Therapeutics plc (Nasdaq: HZNP) today

Neuroimmunol neuroinflammOrhan aktasBrian weinshenkerTina venturaHans peter hartungRay gordonRachel vannProduct communicationsEuropean commissionDrug administrationResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisEfficacy comparisonFirst adjudicated attack